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SHORT SUMMARY
 
A systematic literature review of the incidence of primary 
glomerulonephritis is presented. 40 papers published between 1980 
and 2010 were critically appraised and included in the review. 
Overall, incidence was found to be between 0.2 and 2.5 /100 
000/year in adults with lower incidence rates in children, for most 
types of glomerulonephritis. 
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ABSTRACT
 
Background 
Little is known about the worldwide variation in incidence of primary 
glomerulonephritis. The objective of this review is to critically appraise 
studies of incidence published 1980­2010 so that an overall view of trends 
of these diseases can be found. This will provide important information for 
determining changes in rates and understanding variations between 
countries. 
Methods 
All relevant papers found through searches of Medline, Embase and 
ScienceDirect were critically appraised and an assessment was made of 
the reliability of the reported incidence data. 
Results 
This review includes 40 studies of incidence of primary glomerulonephritis 
from Europe, North and South America, Canada, Australasia and the 
Middle East. Rates for the individual types of disease were found to be in 
adults, 0.2/100 000/year for membrano­proliferative glomerulonephritis, 
0.2/100 000/year for mesangio­proliferative glomerulonephritis, 0.6/100 
000/year for minimal change disease, 0.8/100 000/year for focal 
segmental glomerulosclerosis, 1.2/100 000/year for membranous 
nephropathy and 2.5/100 000/year for IgA nephropathy. Rates were 
lower in children at around 0.1/100 000/year with the exception of 
minimal change disease where incidence was reported to be 2.0/100 
000/year in Caucasian children with higher rates in Arabian children 
(9.2/100 000/year) and Asian children (6.2­15.6/100 000/year). 
Conclusions 
This study found that incidence rates of primary glomerulonephritis vary 
between 0.2/100 000/year and 2.5/100 000/year. The incidence of IgA 
nephropathy is at least 2.5/100 000/year in adults: this disease can exist 
subclinically and is therefore only detected by chance in some patients. In 
addition, referral policies for diagnostic biopsy vary between countries. 
This will affect the incidence rates found. 
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INTRODUCTION
 
Although much is known about clinical characteristics and natural history 
of the primary glomerulopathies, very little information on the 
epidemiology of these diseases is available from reviews. Insight into the 
baseline incidence of glomerulonephritis throughout the world can provide 
important information on trends of disease occurrence by sex, age and 
geographical location. New vaccines are being introduced and concerns 
have been raised about the potential associated risk of autoimmune 
diseases (46,47). It is therefore of interest to know what the baseline 
incidence rates across the world are so that concerns about possibly 
associated increased incidence rates of autoimmune diseases, such as 
glomerulonephritis, can be evaluated. 
To our knowledge no other systematic review of incidence of the most 
common of the primary glomerulopathies has been conducted in the last 
three decades. In this paper we perform a systematic review, critically 
appraising studies of incidence of primary glomerulonephritis throughout 
the world. 
Method 
Searches of the Medline, EMBASE and Science Direct databases (1980 – 
June 2007) were carried out using the search terms ‘glomerulonephritis,’ 
‘IgA nephropathy’, ‘membranous nephropathy’, ‘membranoproliferative 
glomerulonephritis’, ‘mesangial proliferative glomerulonephritis’, ‘minimal 
change disease’, ‘focal segmental glomerulosclerosis’, ‘postinfectious 
glomerulonephritis’, ‘idiopathic crescentic proliferative glomerulonephritis’, 
‘ANCA­associated necrotising crescentic glomerulonephritis’, ‘anti­
glomerular basement membrane disease’, ‘kidney disease’, ‘incidence’, 
‘incid*’ and ‘epidemiology.’ In Medline, the individual disease names were 
searched for as well as the term ‘glomerulonephritis’ because this MeSH 
term does not include all types of glomerulonephritis as daughter terms in 
its hierarchical structure. 
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The inclusion criteria were that the studies reported original work, that the
 
study reported incidence of specific forms of glomerulonephritis with 
reference to a denominator population, that the estimates of population 
size and person­time contributed were accurate and that efforts had been 
made to ascertain all incident cases. When assessing the likelihood of 
missing incident cases, papers were evaluated as follows: 1) for case 
finding studies, did the authors ensure that all of the subjects contributing 
to incidence denominator data would have been eligible to have the 
disease diagnosed and did the authors check all relevant medical records? 
2) For all studies, were cases checked to ensure that they were incident 
and not prevalent? 3) For all studies, did the authors ensure that the 
cause of glomerulonephritis was autoimmune and not secondary to 
another disease? Where possible we only included incidence rates for 
cases of glomerulonephritis caused by autoimmunity, determination of 
which relied on information given in the paper. 
The titles and abstracts of all of the studies produced by the searches 
were reviewed and those papers accepted for inclusion in the study were 
appraised. Studies published in English, French, German, Spanish or 
Dutch were included. Review papers identified were searched for 
secondary references reporting on original research; secondary references 
found from any of the other papers reviewed were also included. 
A standard data abstraction form was used to record all details of the 
papers reviewed; a copy of this is given in the Appendix, figure 1A. Each 
study was scored for accuracy of the incidence rates it presented and was 
classified as being at low, medium or high risk for under­ or over­
estimation of reported incidence rates by considering the reliability of 
numerator and denominator data. For instance, inclusion of prevalent 
cases or those thought not to be caused by autoimmunity will have led to 
overestimated rates as will underestimated denominator data. Conversely, 
missing cases or an overestimated denominator (e.g. a catchment area 
from which not all inhabitants had access to hospital services) would be 
considered to have resulted in underestimated incidence rates. 
Explanations provided by the papers’ authors as to why incidence rates 
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were as expected or whether they were considered to be an over­ or
 
underestimate of the true incidence rate were taken into account in this 
process. If the extent of likely error was considered to be very great, the 
study was excluded. To minimise subjectivity, this assessment was agreed 
between two of the authors and random checks were performed to ensure 
consistency. Rates are presented as the number of cases/100 000/year 
and where sufficient data were given in the paper, rates were checked for 
accuracy. Guidelines were followed in the reporting of this study to ensure 
that key information was presented (1). 
Results 
The results of the database searches with the number of included and 
excluded papers are given in figure 1; the excluded references are 
available on request from the authors. 
Most of the papers rejected at abstract review stage did not report on 
primary and autoimmune glomerulonephritis and had been found from the 
search using ‘kidney disease’ as the search term. Of the remaining 
papers, reasons for rejecting included those reporting on an ill sub­group 
of the population (e.g. those with systemic lupus erythematosus), those 
that reported on prevalence and not incidence, review papers and those 
that gave incidence rates as a percentage of people who had a renal 
biopsy. 
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5144 papers identified in 
database search 
5058 papers rejected after abstract 
review 
106 full 
papers 
appraised 
81 papers rejected 
40 full papers included in 
review 
40 reported on treatment only 
208 reported on incidence of another 
disease 
3996 did not report on GN 
43 reported on GN that was not AI in 
origin 
94 reported on a population who were ill 
with another disease 
68 reported on GN with another disease 
5 foreign language papers 
31 reported features of GN 
78 reported a case series 
349 did not report incidence 
21 reported prevalence 
125 were reviews 
4 reported on a population who were ill 
with another disease 
4 had incomplete or incorrect data 
9 duplicated data given in other studies 
21 gave incidence as % of biopsies 
6 reported on incidence of another disease 
1 did not give enough information 
3 did not report on GN 
5 did not specify the type of GN 
2 reported prevalence or included 
prevalent cases 
19 were reviews 
16 secondary papers appraised 
7 did not report incidence 
Figure 1: Results of the database searches showing the number of 
references found, those excluded and the final number of papers included 
in this review. (GN = glomerulonephritis; AI = autoimmune) 
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For some types of glomerulonephritis, the terms used by authors varied, 
some using the term to describe clinical presentation or syndrome for 
example crescentic proliferative (2) or crescentic glomerulonephritis (3­
5), nephrosis (2,6), rapidly progressive glomerulonephritis (7,8), acute 
glomerulonephritis (9) and acute nephritis (10) whereas others used non­
specific terms such as vasculitis (11­15) and total glomerulonephritis (9). 
These incidence rates have been excluded from the review because it was 
impossible to determine the extent to which these papers reported on 
primary and autoimmune glomerulonephritis. 
Descriptions of the studies are given in table 1 and incidence rates are 
displayed in forest plots showing rates for children in figure 2 and adults 
or all ages in figure 3. Appendix 1, table 1A includes a table of all rates 
presented in the forest plots. Most of the studies included in this review 
investigated populations in Australasia (3,11,16), Europe (2,4­6,9,14,17­
30), and North America (31­36) with five studies from the Middle East 
(13,37­40), two studies from South America (15,41), one study from 
Japan (42) and one study from Tunisia (43). Findings for the different 
subtypes of glomerulonephritis are summarised below. 
IgA nephropathy: four studies reported rates in children and teenagers: 
0.03 /100 000/year (CI95 0­0.1) in Venezuela (41), 0.08 (CI95 0.01­0.46) 
/100 000/ year (1975­1984) to 0.57 (CI95 0.23­1.18) /100 000/ year 
(1985­1994) (0­17 years) in Tennessee, US (33), 4.5 /100 000/year (0­
15 years) in Japan (42) and 0.31 /100 000/year (0­15 years) in Italy (25) 
(CI95 indicates 95% confidence interval). The difference in these rates 
may be explained by the study type: the Japanese study was a screening 
study and therefore detected subclinical cases of IgA nephropathy as well 
as including three possibly prevalent cases (total 37) who did not have 
previous screening results recorded. In contrast, the studies from 
Tennessee and Italy were based on renal biopsy and the study from 
Venezuela used chart reviews of symptoms and some biopsy results. 
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Most of the other studies were prospective, reporting rates from 0.2 /100
 
000 /year to 2.8 /100 000/year (2­6,13,18,19,21,27,43); the 
retrospective studies reported a similar range of rates, from 0.4 /100 
000/year to 2.9 /100 000/year (9,11,14,20,29,30,35,36,38,39). Two 
studies reported incidence rates of 5.0/100 000/year (28) and 5.7/100 
000 /year in males (11) but both had high biopsy rates which is likely to 
have contributed to the greater incidence rates found. Many of the studies 
included in this review were conducted between 1970 and 1990; no trend 
in incidence rates with time was discernable. Sixteen studies (3­
6,9,11,13,14,20,21,25,27,29,32,35,38) reporting rates used 
immunofluorescence in diagnosing IgA nephropathy. 
Membranous nephropathy: two studies (25,31) gave incidence rates in 
children and adolescents: 0.05 /100 000/year (1985­1993) to 0.09 /100 
000/year (1993­2002) (6 months – 19 years) in Ottawa­Hull Canada (31) 
and 0.02 /100 000/year (0­15 years) in Italy (25). For the other studies, 
most were prospective and reported incidence rates between 0.3/100 000 
/year and 1.4 /100 000/ year (2­6,13,18,19,21,27,28); the retrospective 
studies reported incidence to be between 0.2/100 000/year and 1.3/100 
000/year (9,11,14,15,20,26,29,30,35,38,39,44). Not many studies 
reported on differences in rates between males and females. In those that 
did, the numbers were low and no confidence intervals or indications of 
statistical significance for differences in incidence rates were available. 
Three studies (6,9,11) suggested the rates were higher in males than 
females whereas El Reshaid et al. (13) reported the opposite. Taking into 
account the methods used in the studies presented, it is not thought that 
there has been a change in incidence between 1970 and 2000. The 
studies that used retrospectively collected data are likely to have missed 
cases and therefore underestimate the incidence rates. There was 
insufficient information to conclude reliably whether there is a difference 
in risk between males and females. Our best estimate of the incidence is 
1.2 /100 000/year. 
Membrano­proliferative glomerulonephritis: thirteen studies were 
retrospective and six were prospective; the range of incidence rates in all 
9 
studies was between 0.14 /100 000/year and 0.93 /100 000/year. Over
 
time, incidence appears to have decreased from around 0.7 /100 
000/year in the 1970s (3,6,18) to 0.2 in the 1990s (2,5,9,14) with the 
exception of Covic et al (26) who report a rate of 0.93/100 000/year in 
2004. Covic et al (26) link this to the higher rates of streptococcal 
infection and hepatitis B and C in their population; they also note a 
decrease in the prevalence of membranoproliferative glomerulonephritis 
between 1995 and 2004 which they believe is associated with 
improvements in income, sanitation, social and medical infrastructure. 
Simon et al. (2,6) noted that there was an association between 
streptococcal infection and the onset of membrano­proliferative 
glomerulonephritis and that the decreases in incidence rates of 
membrano­proliferative and post­streptococcal glomerulonephritis were 
closely linked. Other differences in rates are noticeable: Hachicha et al. 
(43) found the highest rate of membrano­proliferative glomerulonephritis 
although this is probably an over­estimate of the true rate; in New 
Zealand (3) an incidence rate five times higher in Polynesians than in non­
Polynesians was reported. This may indicate an infection related 
glomerular­specific injury. Two studies (2,3) reported on the incidence of 
type I membrano­proliferative glomerulonephritis, two studies (9,14) 
reported that 68% of their cases were type I and in a third study (30) 
90% were type I; the remaining studies (3,5,6,11,18,19,25­
27,31,38,39,45) did not specify the type of membrano­proliferative 
glomerulonephritis diagnosed. 
Mesangial proliferative glomerulonephritis : four studies included 
were prospective and three were retrospective; all gave incidence rates 
between 0.2 /100 000/year and 1.1/100 000/year (3,5,6,26,27,44). In 
order to differentiate mesangial proliferative glomerulonephritis from IgA 
nephropathy, immunofluorescence should be used. All seven studies used 
immunofluorescence in their studies but four reported that this was not 
performed on all biopsies (26,27,30,44) giving a potential overestimation 
of the incidence rate. The only study to make the distinction between IgA 
nephropathy and mesangial proliferative glomerulonephritis without IgA 
deposits was that by Schena et al (5), who found an incidence rate of 
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0.16/100,000/year therefore it is likely the ‘true’ incidence rate of
 
mesangial proliferative glomerulonephritis is at the lower end of the range 
given. 
Minimal­change disease: in children, minimal change disease has been 
found to cause over 75% of cases of nephrotic syndrome (46). Seven 
studies reported on incidence of nephrotic syndrome, which would 
produce a slight overestimation of incidence of minimal change disease 
(22,24,34,37,40,41); three studies reported on incidence of minimal 
change nephrotic syndrome (23,25,31). Incidence rates in children were 
between 0.23 /100 000/year and 15.6 /100 000/year (22­
25,31,34,37,40,41). The rates were reported with respect to ethnic origin 
and differences were noted: 0.23 ­2.8/100 000/year in Caucasian children 
(22,24,25,31); 2.4/100 000/year in Hispanic children (41); 3.4 /100 
000/year in Afro­Caribbean children (22); 7.2­11.6/100 000/year in 
Arabian children (37,40) and 6.2­15.6/100 000/year in Asian children who 
resided in the UK (22,23). 
In the remaining studies, retrospective and prospective studies reported 
similar rates between 0.2/100 000/year and 0.8/100 000/year in adults 
(3,5,9,11,15,18,21,26,27,29,30,35,38,39,44); no trend of changes over 
time was found. Taking into account the accuracy of these rates, our best 
estimate of incidence of minimal change disease in adults is 0.6/100 
000/year. 
Focal segmental glomerulosclerosis: most rates, whether from 
prospective or retrospective studies, were between 0.2 /100 000/year and 
1.1 /100 000/year; the Australian study reported the highest rates of 
2.5/100 000/year in males and 1.8/100 000/year in females. The latter 
may be due to the fact that in Australia, people are referred for biopsy 
more often than in other countries included in this review (11). In the 
three studies that investigated differences in rates between males and 
females, incidence appeared to be higher in males (9,11,13). However no 
indication was given of the statistical significance of these differences and 
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given the fact that the numbers of cases were low, they may have arisen
 
by chance. 
Other types of glomerulonephritis: Incidence rates were presented for 
other types of glomerulonephritis, however these were limited to just one 
or two studies per disease type. Details are given in the forest plots: 
generally these rates were low at less than 1.0 /100 000/year. However 
Becquet et al. (16) in their study of post­infectious glomerulonephritis in 
French Polynesia, reported an incidence rate of 18/100 000/year; this is 
likely to be an underestimate of the true rate. This country had a higher 
rate of bacterial infections due to the climatic conditions, greater numbers 
of people sharing residences, low socioeconomic level and a lower use of 
medical care due to cultural beliefs; these factors are all thought to 
contribute to this higher incidence rate. 
Accuracy of incidence rates 
There are a number of components to assess when considering the 
incidence rates presented. Indication of likely accuracy of rates has been 
given in table 1. Of key importance is whether the cases included in the 
numerator were new cases: six studies reported in their methods section 
that only new cases were included (2,4,6,9,22,24,36,37). As 
glomerulonephritis is diagnosed by biopsy, the more liberal the biopsy 
policy, the greater the possibility of detecting all cases of the disease. 
Some studies gave their biopsy rate per head of population: these are 
given in table 1 and vary between 1.08 and 24.7 /100 000/year 
(6,11,14,18,19,21,26­30,35,38,39,44). 
Discussion 
This literature review found incidence rates for different types of primary 
autoimmune glomerulonephritis to be between 0.2/100 000/year and 
2.5/100 000/year in adults. Most studies were from the US and France 
therefore it is difficult to draw conclusions regarding variability of rates 
with geographical location or ethnicity. Given that glomerulonephritis can 
exist subclinically, and given differences in access to renal biopsy between 
different healthcare systems, it is likely that geographical variations in 
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incidence rates found can be explained by differences in diagnosis rather
 
than by genuine difference in disease frequency. 
It is useful to note the type of studies undertaken to determine incidence 
of glomerulonephritis: in reviews of incidence of other autoimmune 
diseases (47,48), prospective studies are thought to have given more 
accurate rates than retrospective studies. However, in the studies 
presented here the rates reported were consistent irrespective of the 
study type. 
Most studies used biopsy to diagnose the disease for the majority of cases 
however only five studies (3,21,27,36,40) reported the guidelines used for 
diagnosis. Classification of the disease and detection threshold of signs 
and symptoms may cause variation in incidence rates between studies 
(11,14,21) and the lack of a central histopathology review may have 
caused within­study variations (14). Wyatt et al. (32) reported that over 
time there was an increased recognition of IgA nephropathy therefore the 
incidence rates from the end of the study may be more accurate. Similarly 
Mazzuchi et al (15) reported rates using a national registry and found an 
increase in incidence with time they reported to be due to a greater 
awareness of the disease and earlier diagnosis. 
Cases of IgA nephropathy can exist subclinically and therefore will only be 
diagnosed through routine urinary tests or if a patient presents with 
severe symptoms (27): Simon et al. (6) reported that 60% of cases of 
idiopathic IgA nephropathy were discovered by chance through routine 
testing as part of a medical examination in employment. Screening 
populations for conditions that can exist subclinically will produce higher 
and more accurate incidence rates especially when done routinely so that 
prevalent cases are not included in the incidence rate. In this review one 
study (42) used a regular screening program to find cases and the rate 
produced was greater by nearly an order of magnitude than other 
comparable incidence rates. Sehic et al. (33) reported that many cases of 
IgA are never diagnosed and that limited access to medical care for those 
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of lower socio­economic status may explain some failure to diagnose in 
this study. 
There is the possibility of cases of secondary glomerulonephritis being 
included as primary cases particularly in retrospective studies; this would 
lead to an overestimation of incidence rates. There are links, for example 
between membrano­proliferative glomerulonephritis and hepatitis B or 
hepatitis C. Variations between countries in terms of rates of infections 
will contribute to differences in incidence rates. 
One of the key factors in explaining differences in incidence rates of 
glomerulonephritis is the difference in referral and biopsy policies between 
different countries and even between regions of countries (14,21,28,29). 
Briganti et al. (11) found higher incidence rates of minimal change disease 
and focal segmental glomerulosclerosis than other studies. They claim this 
may be as a result of a more liberal biopsy policy, leading to the detection 
of less well­defined or asymptomatic cases. In contrast, The New Zealand 
Glomerulonephritis Study (3) noted that children and teenagers with 
postinfectious GN or minimal change nephropathy are rarely biopsied and 
older patients may also be less likely to have biopsies taken than younger 
adults. There is evidence that Polynesians have poorer access to 
healthcare resources in New Zealand than others and in this study, a high 
proportion of Polynesian patients presented for the first time with end­
stage renal failure, making it impossible to reach a specific diagnosis. Lack 
of access to healthcare may also have resulted in prevalent cases being 
included in the incidence rates for glomerulonephritis in this population. 
Naumovic et al (30) reported that their low biopsy rate (1.08/100 
000/year) may be due to economic sanctions and that elderly people and 
those with diabetes do not routinely undergo biopsy. Incidence was found 
to be lower in African­American children compared to Caucasian children 
(33). The study authors suggested this may be because the decision to 
perform a biopsy for those suspected to have mild disease was referred to 
their parents who may have been less likely than Caucasian parents to 
give their consent; records were not available for the number of biopsies 
refused (17). 
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Renal biopsy policy also affects diagnosis rates in the elderly: a number of 
studies reported increases in the number of elderly patients biopsied as a 
result of a change in policy and increasing age of the population 
(2,4,9,32) with Stratta et al. (9) reporting that rates of elderly patients 
diagnosed increased from 1.6% in 1970 to 20.4% in 1994. Wyatt et al. 
reported an increase in incidence at 45 years and over which was thought 
to be due to a more proactive attitude towards conducting diagnostic 
procedures in the elderly. It is likely that incidence in older people is 
underestimated as not all cases were referred to specialists or underwent 
biopsies (9). 
Conclusion 
Reported incidence rates of glomerulonephritis in adults varied between 
0.2 and 2.5 /100 000 /year depending on the type of glomerulonephritis. 
Incidence in children was generally lower with most rates around 0.1 /100 
000 /year; two exceptions to this were that incidence of minimal change 
disease in children was around 2.0 /100 000/year and a screening study 
that reported a rate of IgA nephropathy of 4.5 /100 000 /year in children 
in Japan. 
The reported incidence rates are likely to underestimate true rates of IgA 
nephropathy as this disease can exist subclinically and may never be 
detected however other types of glomerulonephritis may be overestimated 
due to relapses and prevalent cases being counted as incident. There is 
variation in biopsy policy between countries, which affects the incidence 
rates found. Incidence in older people appears to have increased over 
time: this is considered to be due to greater inclusion of this age group in 
referrals for biopsy rather than due to a genuine increase in disease 
occurrence. 
Acknowledgements 
This work was supported by a grant from GSK Biologicals. The authors do 
not have any conflicts of interest to declare. 
15 
16
 
Reference List 
(1)	 Stroup DF, Berlin JA, Morton SC, et al. Meta­analysis of observational 
studies in epidemiology. A proposal for reporting. JAMA 2000; 283: 2008­
12 
(2)	 Simon P, Ramee MP, Boulahrouz R, et al. Epidemiologic data of primary
 
glomerular diseases in western France. Kidney Int 2004; 66: 905­8
 
(3)	 The New Zealand Glomerulonephritis Study: introductory report. Clin
 
Nephrol 1989; 31: 239­46
 
(4)	 Simon P, Charasse C, Autuly V, et al. Epidemiology of primary glomerular 
disease in the elderly. A prospective study during a 15­year period. 
Contrib Nephrol 1993; 105: 161­6 
(5)	 Schena FP, Italian group of renal immunopathology. Survey of the Italian 
registry of renal biopsies. Frequency of the renal diseases for 7 
consecutive years. Nephrol Dial Transplant 1997; 12: 418­26 
(6)	 Simon P, Ramee MP, Autuly V, et al. Epidemiology of primary glomerular 
diseases in a French region. Variations according to period and age. 
Kidney Int 1994; 46: 1192­8 
(7)	 Ots M, Salupere V, Uibo R. Regional incidence of rapidly progressive 
glomerulonephritis in Estonia. Nephrol Dial Transplant 1997; 12: 2794­6 
(8)	 Andrassy K, Kuster S, Waldherr R, Ritz E. Rapidly progressive
 
glomerulonephritis: analysis of prevalence and clinical course. Nephron
 
1991; 59: 206­12
 
(9)	 Stratta P, Segoloni GP, Canavese C, et al. Incidence of biopsy­proven
 
primary glomerulonephritis in an Italian Province. American Journal of
 
Kidney Diseases 1996; 27: 631­9
 
(10)	 Dawson KP. A comparative study of the clinical patterns of acute 
glomerulonephritis from a high and a low incidence area of New Zealand. 
N Z Med J 1982; 95: 262­4 
(11)	 Briganti EM, Dowling J, Finlay M, et al. The incidence of biopsy­proven 
glomerulonephritis in Australia. Nephrol Dial Transplant 2001; 16: 1364­7 
(12)	 Hurtado A, Johnson RJ. Hygiene hypothesis and prevalence of 
glomerulonephritis. Kidney Int 2005; 68: S62­S67 
(13)	 El Reshaid W, El Reshaid K, Kapoor MM, Madda JP. Glomerulopathy in 
Kuwait: the spectrum over the past 7 years. Ren Fail 2003; 25: 619­30 
(14)	 Rivera F, Lopez­Gomez JM, Perez­Garcia R, Spsnish Registry of 
Glomerulonephritis. Frequency of renal pathology in Spain 1994­1999. 
Nephrol Dial Transplant 2002; 17: 1594­602 
(15)	 Mazzuchi N, Acosta N, Caorsi H, et al. [Frequency of diagnosis and clinic 
presentation of glomerulopathies in Uruguay]. [Spanish]. Nefrologia 2005; 
25: 113­20 
17 
(16)	 Becquet O, Pasche J, Gatti H, et al. Acute post­streptococcal 
glomerulonephritis in children of French Polynesia: a 3­year retrospective 
study. Pediatric nephrology (Berlin, Germany) 2010; 25: 275­80 
(17)	 Frimat L, Bellou­Zerrouki M, Kessler M. [Annual incidence of IgA 
nephropathy (Berger disease) and Henoch­Scholein purpura in eastern 
France]. [French]. Presse Med 1994; 23: 1879 
(18)	 Abdulmassih Z, Makdassi R, Bove N, et al. [Epidemiology of primary 
glomerulonephritis in Picardie]. [French]. Ann Med Interne 1990; 141: 
129­33 
(19)	 Berthoux F. [Annual incidence of glomerulonephritis in the extended 
Rhone­Alpes region in 1987­1988]. [French]. Presse Med 1990; 30: 14­7 
(20)	 Grupo de Estudio de la Sociedad Espanola de Nefrologia. Variationes de la 
incidencia de las distintas formas de glomerulonefritis primarias en 
Espana. Un estudio de 8545 biopsias renales. Nefrologia 1988; 8: 105­13 
(21)	 Tiebosch AT, Wolters J, Frederik PF, et al. Epidemiology of idiopathic 
glomerular disease: a prospective study. Kidney Int 1987; 32: 112­6 
(22)	 Sharples PM, Poulton J, White RH. Steroid responsive nephrotic syndrome 
is more common in Asians. Arch Dis Child 1985; 60: 1014­7 
(23)	 Feehally J, Kendell NP, Swift PGF, Walls J. High incidence of minimal 
change nephrotic syndrome in Asians. Arch Dis Child 1985; 60: 1018­20 
(24)	 McKinney PA, Feltbower RG, Brocklebank JT, Fitzpatrick MM. Time trends 
and ethnic patterns of childhood nephrotic syndrome in Yorkshire, UK. 
Pediatr Nephrol 2001; 16: 1040­4 
(25)	 Coppo R, Gianoglio B, Porcellini MG, Maringhini S. Frequency of renal 
diseases and clinical indications for renal biopsy in children (report of the 
Italian National Registry of Renal Biopsies in Children). Group of Renal 
Immunopathology of the Italian Society of Pediatric Nephrology and Group 
of Renal Immunopathology of the Italian Society of Nephrology. Nephrol 
Dial Transplant 1998; 13 2: 293­7 
(26)	 Covic A, Schiller A, Volovat C, et al. Epidemiology of renal disease in 
Romania: a 10 year review of two regional renal biopsy databases. 
Nephrol Dial Transplant 2006; 21: 419­24 
(27)	 Rychlik I, Jancova E, Tesar V, et al. The Czech registry of renal biopsies. 
Occurrence of renal diseases in the years 1994­2000. Nephrol Dial 
Transplant 2004; 19 12: 3040­9 
(28)	 Wirta O, Mustonen J, Helin H, Pasternack A. Incidence of biopsy­proven 
glomerulonephritis. Nephrology Dialysis Transplantation 2008; 23: 193­
200 
(29)	 Hanko JB, Mullan RN, O'Rourke DM, et al. The changing pattern of adult 
primary glomerular disease. Nephrology Dialysis Transplantation 2009; 24 
10: 3050­4 
18 
(30)	 Naumovic R, Pavlovic S, Stojkovic D, Basta­Jovanovic G, Nesic V. Renal 
biopsy registry from a single centre in Serbia: 20 years of experience. 
Nephrol Dial Transplant 2009; 24: 877­85 
(31)	 Filler G, Young E, Geier P, et al. Is there really an increase in non­minimal 
change nephrotic syndrome in children? Am J Kidney Dis 2003; 42: 1107­
13 
(32)	 Wyatt RJ, Julian BA, Baehler RW, et al. Epidemiology of IgA nephropathy 
in central and eastern Kentucky for the period 1975 through 1994. Central 
Kentucky Region of the Southeastern United States IgA Nephropathy 
DATABANK Project. J Am Soc Nephrol 1998; 9: 853­8 
(33)	 Sehic AM, Gaber LW, Roy S, III, et al. Increased recognition of IgA 
nephropathy in African­American children. Pediatr Nephrol 1997; 11: 
435­7 
(34)	 Kim JS, Bellew CA, Silverstein DM, et al. High incidence of initial and late 
steroid resistance in childhood nephrotic syndrome. Kidney Int 2005; 68 
3: 1275­81 
(35)	 Swaminathan S, Leung N, Lager DJ, et al. Changing incidence of 
glomerular disease in Olmsted County, Minnesota: a 30­year renal biopsy 
study. Clin J Am Soc Nephrol 2006; 1: 483­7 
(36)	 Fischer EG, Harris AA, Carmichael B, Lathrop SL, Cerilli LA. IgA 
nephropathy in the triethnic population of New Mexico. Clinical Nephrology 
2009; 72: 163­9 
(37)	 Elzouki AY, Amin F, Jaiswel OP. Primary nephrotic syndrome in Arab 
children. Arch Dis Child 1984; 29: 253­5 
(38)	 Al Arrayed A, George SM, Malik AK, et al. The spectrum of glomerular 
diseases in the kingdom of Bahrain: an epidemiological study based on 
renal biopsy interpretation. Transplant Proc 2004; 36: 1792­5 
(39)	 Al Arrayed A, Shariff S, Maamari MMA. Kidney Disease in Bahrain: A 
Biopsy­Based Epidemiological Study. Transplant Proc 2007; 4: 875­8 
(40)	 Zaki M, Helin I, Manandhar DS, Hunt MCJ, Khalil AF. Primary nephrotic 
syndrome in Arab children in Kuwait. Pediatric Nephrology 1989; 3: 218­
20 
(41)	 Orta­Sibu N, Lopez M, Moriyon JC, Chavez JB. Renal disease in children in 
Venezuela, South America. Pediatric Nephrology 2002; 17: 566­9 
(42)	 Utsunomiya Y, Koda T, Kado T, et al. Incidence of pediatric IgA 
nephropathy. Pediatr Nephrol 2003; 18: 511­5 
(43)	 Hachicha J, Bellaj A, Sellami F, et al. [Primary glomerular nephropathies in 
southern Tunisia]. [French]. Presse Med 1992; 21: 1914 
(44)	 Heaf J, Lokkegaard H, Larsen S. The epidemiology and prognosis of 
glomerulonephritis in Denmark 1985­1997. Nephrology Dialysis 
Transplantation 1999; 14: 1889­97 
19 
(45)	 Simon P, Ramee MP, Autuly V, et al. [Epidemiology of primary 
glomerulopathies in a French region. Variations as a function of age in 
patients]. [French]. Nephrologie 1995; 16: 191­201 
(46)	 International Study of Kidney Disease in Children. Nephrotic syndrome in 
children: Prediction of histopathology from clinical and laboratory 
characteristics at time of diagnosis. Kidney Int 1978; 13: 159­65 
(47)	 McGrogan A, Seaman HE, Wright JW, de Vries CS. The incidence of 
autoimmune thyroid disease: A systematic review of the literature. Clin 
Endocrinol 2008; 69: 687­96 
(48)	 McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of 
Guillain­Barre Syndrome worldwide: a systematic literature review. 
Neuroepidemiolgy 2009; 32: 150­63 
20 
Table 1:  Details  of  diagnosis  of  cases  and  population  covered  for  each  of  the  studies  included  in  this  report 

 
Study  Cases  RUE  ROE Biopsy 
rate  
Description  
Hachicha et al. (43) 
Study  type:  Retrospective 
hospital  record review  
Location:  Sfax, Tunisia  
611 **  ***  Not  
given  
Case  definition: >14 years. Renal  biopsy  in  230 cases; histological  disease type 
determined.  Very few study details  given.  Case  identification:  No  details  given.  
Utsunomiya  et al. (42) 
Study  type:  Prospective 
screening  study  
Location:  Yonago  City, 
Japan  
37 **  **  99.5% Case  definition: Initial  screening  of  first urine  of  morning;  second  screening  of  
those with proteinuria,  occult blood  and  urinary sediment.  Those  with glucosuria 
were referred. Follow­up  for  a few months. Case identification: All  students  aged  
6­15 years screened annually.  Indication  for renal  biopsy  determined  according  to 
criteria.  Records of  previous  screenings  checked to identify  new  cases. 
Briganti  et al. (11) 
Study  type:  Retrospective  
Location:  Victoria,  Australia 
1147 * * 21.5 Case  definition: Renal  biopsy.  Case  identification: Retrospective review  of  
pathology  reports  of  all  biopsies;  evaluated  by  light  microscopy and  
immunofluorescence  or  immunohistochemistry;  majority assessed by  electron  
microscopy.  No  details  available  of  clinical  findings  or  indication  for biopsy.  
The  New  Zealand  
Glomerulonephritis  Study  (3) 
Study  type:  Prospective 
Location:  New  Zealand  
803 ***  * ‘Liberal’  Case  definition: >  14 years. Renal  biopsy  material  examined  using  light,  
immunofluorescence  and  electron  microscopy. Uniform  histological  classification  
agreed;  all  renal  biopsies  re­evaluated  independently  using  Churg  and  Sobin  
classification.  Case  identification:  4 nephrology  centres covering 75% of  the 
Polynesian  and  84% of  the non­Polynesian  populations  used.  
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Study  Cases  RUE  ROE Biopsy 
rate  
Description  
Becquet  et al. (16) 12 * * Not  Case  definition: <  15 years. Diagnostic  criteria  were  microscopic  or  macroscopic 
Study  type:  Retrospective  given  haematuria,  decreased C3 fraction of  the complement  evidence  of  recent 
Location:  French  Polynesia streptococcal infection established  by  presence of  elevated  anti­streptococcal 
antibody  titres. Case  identification: Admitted  to  one  hospital.  
Frimat  et al. (17) Not  * * Not  Case  definition: Prospective longitudinal  cohort  study;  >15 years. Diagnoses  
Study  type:  Prospective given  given  based  on  renal  biopsy  and  checked by  pathologist.  Study  restricted to  half  
Location:  East  France  geographical  area to ensure  all  biopsies  included.  Case identification: 17 renal 
units. 
Abdulmassih  et al.  (18) 266 **  * Case  definition: >15 years, diagnosed  by  biopsy.  Case  identification: All  
Study  type:  Retrospective  ’76­80 7.2 biopsies  for  the area examined  in  one  lab.  
Location:  Picardy, France  ’81­85 8.6 
Berthoux et al. (19) Not  * * 13.0 Case  definition: Renal  biopsy.  Case  identification: Sent questionnaire  in  1989 to 
Study  type:  Prospective given  all  nephrology  services; also  provided  information for denominator.  
Location:  Rhone­Alps,  
France  
Simon  et al. (6) 480 * * Case  definition: Renal  biopsy  specimens processed and  stained  for light  
Study  type:  Prospective ’76­80 18.7 microscopy and  immunohistory;  electron  microscopy not  systematically performed.  
Location:  St. Brieuc,  France ’81­85 20.1 Case  identification: Biopsy  performed at  hospital  nephrology  department;  
’86­90 16.2 collaborated  with major medical  screening institutions.  
Simon  et al. (4) 131 Not  Case  definition: >  60 years old,  otherwise,  as  above.  
As  above  given  
Simon  et al. (2) 898 Not  Case  definition and  identification: As  above.  
As  above  given  
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Study  Cases  RUE  ROE Biopsy 
rate  
Description  
Simon  et al. (45) 898 Not  Case  definition and  identification: As  above.  
As  above  given  
Schena  et al. (5) 1293 **  **  ~ 4.5 Case  definition: Renal  biopsies  mainly  evaluated  by light­microscopy  and  
Study  type:  Prospective immunofluorescence;  electron­microscopy  used  in  38% of  cases. Case 
Location:  Italy  identification: Biopsies  collected  at  Italian  renal  units.  
Coppo  et al.  (25) 256 **  **  Not  Case  definition: 0­15 years; renal  biopsy  analysed  by  light  microscopy and  
Study  type:  Prospective given  immunofluorescence;  electron  microscopy used  in  32% of  cases. Case 
Location:  Italy  identification: Renal  units  where biopsies  were performed. 
Stratta et al. (9) 454 * * Not  Case  definition: >15 years, renal  biopsy  taken  during  time  period.  Biopsies  
Study  type:  Retrospective  given  underwent  light  microscopy and  immunofluorescence;  electron microscopy  not  
Location:  City/ Province of  routinely  used.  Case  identification:  3 nephrology  centres in  city (provided  renal 
Turin,  Italy  biopsies  to  virtually entire  area); those  outside  region were excluded.  
Rivera et al. (14) Not  ***  ***  4.8 Case  definition: Primary glomerulonephritis  classified  into eight  groups;  criteria  
Study  type:  Retrospective  given  not  given.  Case  identification: Retrospective  review  of  renal  biopsies  from national  
Location:  Spain  registry.  
Grupo  de  Estudio  de  la  1471 ***  *  Not  Case  definition: Diagnosis  established  from kidney  biopsies  studied  by  light  
Sociedad  Espanola  de  (max.)  given  microscopy and  immunofluorescence.  >14 years. Membranoproliferative  GN  was 
Nefrologia  (20) classified  as  type I  or  type II  Tried to identify  all  primary  cases. Case  
Study  type:  Retrospective  identification: 33 hospitals  responded.  
Location:  Spain  
Wirta  et al.  (28) 958 **  * UH  24.7 Case  definition: Kidney  biopsy;  SNOMED  classification  Case  identification: 
Study  type:  Prospective CH 9.1 Patients receiving a  renal  biopsy  at  the university  or  central hospitals.  
23 
Study  Cases  RUE  ROE Biopsy 
rate  
Description  
Location:  Western Finland  
Heaf et al.  (44) 
Study  type:  Retrospective  
Location:  Denmark  
1762 **  **  3.82 Case  definition: Renal  biopsy  classified  according to  WHO  guidelines  and  presence 
of  immune  deposits.  Case  identification: Renal  biopsy  register. 
Tiebosch  et al.  (21) 
Study  type:  Prospective 
Location:  Areas surrounding 
the cities  of  Heerlen,  
Maastricht and  Sittard,  The 
Netherlands  
129 * * 12.6 Case  definition: Renal  biopsies  processed and  stained  for light  microscopy, 
transmission electron  microscopy  and  immunohistochemistry  and  classified  
according  to WHO  guidelines.  Case  identification: Biopsies  taken  in  direct  referral 
hospitals  for GPs. 
Hanko  et al. (29) 
Study  type:  Retrospective  
Location:  Northern Ireland,  
UK  
907 * * 
‘76­85  
‘86­95  
’96­05 
2.02 
3.86 
7.08 
Case  definition: > 16 years; all  aduct  native  kidney  biopsies  analysed.  Case  
identification: Renal  services in  pathology  department  at  city hospital.  
Sharples  et al.  (22) 
Study  type:  Retrospective  
Location:  Birmingham,  UK  
44 **  ***  Not  
given  
Case  definition: <16 years presenting  with nephrotic  syndrome  responding  to 
corticosteroids.  Nephrotic  syndrome  defined  as  proteinuria  of  at  least  3+ on  Albustix  
testing with oedema  and a  plasma  albumin  concentration  of  25 g/l  or  less. Steroid 
response  defined  as  abolition  of  proteinuria  within eight  weeks of  starting 
prednisolone.  Case  identification: Names  and  hospital  numbers  were traced for all  
admissions  with the main  or  subsidiary  diagnosis  and  responding  to corticosteroid  
treatment. 
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Study  Cases  RUE  ROE Biopsy 
rate  
Description  
Feehally  et al  (23) 
Study  type:  Retrospective  
Location:  Leicestershire, UK  
43 **  **  Not  
given  
Case  definition: <15 years. Minimal  change  nephrotic  syndrome  defined  by  
complete  abolition  of  proteinuria  within four  weeks in  response  to corticosteroids  
with no  hypertension  or  renal impairment.  Some  had  further information  from 
biopsy  material  analysed  by light,  immunofluorescence  and  electron microscopy.  
Case  identification.  From  hospital  records. 
McKinney  et al  (24) 
Study  type:  Retrospective  
Location:  Yorkshire, UK  
194 ***  ***  Not  
given  
Case  definition: 0­15 years. Nephrotic  syndrome  diagnosed  if  proteinuria  was at  
least  3+ on  testing  with albustix,  with hypoalbuminaemia  and  oedema.  Investigated  
response  to corticosteroids.  Case  identification: Primary: listings  provided  by  
paediatricians.  Secondary: inpatient  hospital  episode  statistics; identified  those with 
ICD9  codes  580­583 (acute/chronic  GN,  NS, nephritis,  nephropathy)  590 (infections  
of  the kidney.)  Data  extracted from hospital  notes.  Ethnic  group  determined  by  
surname. 
Rychlik  et al  (27) 
Study  type:  Prospective 
Location:  Czech  Republic  
1932 **  **  5.37 Case  definition: Indications  for biopsy  differed  between  centres. Histological  
evaluation  by  light  microscopy  and  immunofluorescence  performed routinely,  with 
electron  microscopy in  a  number  of  cases. Histological  classification  used  WHO  
recommendations.  Case  identification: Renal  biopsy  records collected  from renal 
units. Questionnaire  used  to collect  relevant data.  
Covic et al  (26) 
Study  type:  Retrospective  
Location:  Moldova  and  
Banat,  Romania  
Not  
given  
**  **  11.3 Case  definition: >18 years; diagnosed  by  renal  biopsy.  Case identification: Two 
large  referral centres. 
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Study  Cases  RUE  ROE Biopsy 
rate  
Description  
Naumovic  et al  (30) Not  ***  **  1.08 Case  definition: >18 years; diagnosed  by  renal  biopsy;  stained  and  analysed  by  
Study  type:  Retrospective  given  light  microscopy.  Case  identification: Nephrology  unit.  
Location:  Serbia  
Al  Arrayed et al  (38) 218 **  **  5.8 Case  definition: Indications  for biopsy:  proteinuria,  unexplained  microscopic or 
Study  type:  Retrospective  macroscopic  haematuria,  systemic disease  with clinical  evidence  of  renal  
Location:  Bahrain  involvement,  unexplained  renal  impairment  and  renal  impairment  in  post­transplant  
patients.  Case  identification: All  renal  biopsies,  nephrectomy  specimens  and  
referral slides  pertaining  to renal  disease  reviewed.  
Al  Arrayed et al  (39) 
As  above  
40 **  **  5.4 Case  definition: As  above.  Case  identification: As  above.  
El  Reshaid  et al  (13) 315 * ***  Not  Case  definition: Histological  diagnosis  of  biopsy  made  on  results  of  light  
Study  type:  Prospective given  microscopy, immunofluorescence  and  electron­microscopy in  selected patients. 
Location:  Kuwait  Case  identification: Patients  screened for glomerulopathy;  those meeting  criteria  
referred for biopsy.  
Zaki et al  (40) 55 **  **  Not  Case  definition: Patients had  oedema,  albuminuria  and  hypoalbuminaemia.  Biopsy 
Study  type:  Prospective given  in  those non­responsive  to steroid medication  over 4 weeks. International  Society of  
Location:  Kuwait  Kidney  Disease  in  Children  guidelines  used.  Case  identification: Children  admitted  
to the paediatric  hospital  departments of  in  Kuwait.  
Elzouki  et al  (37) 19 **  ***  Not  Case  definition: <15 years. Renal  biopsy  performed in  17 of  19 cases.  Standard  
Study  type:  Prospective given  methods  of  light  and  electron  microscopy and  immunofluorescence.  Case  
Location:  Benghazi,  Libya  identification: El­Fateh  Children's  Hospital  and  clinics  in  the area. 
Filler  et al  (31) 159 * **  Not  Case  definition: Diagnosis  made  according  to the International  Study  of  Kidney  
Study  type:  Retrospective  given  Disease  in  Children  criteria,  verified by  chart review.  Case  identification: All  
26 
Study  Cases  RUE  ROE Biopsy 
rate  
Description  
Location:  Ottawa­Hull  inpatients and  outpatients  referred to nephrology  services  included.  Hospital  
region,  Canada admission  database  and  renal  biopsy  records also  checked. 
Wyatt et al  (32) 192 **  * Not  Case  definition: Renal  biopsy  using  direct  immunofluorescence;  standard  criteria. 
Study  type:  Prospective given  Case  identification: Primary method  of  ascertainment by  renal  pathologists,  
Location:  Central and  hospital  records  also  reviewed. 
eastern Kentucky, US  
Swaminathan  et al  (35) 116 **  * Case  definition: Renal  biopsy  evaluated  with light  microscopy, 
Study  type:  Retrospective  ’74­‘83  8.2 immunofluorescence  and  electron  microscopy; diagnosis  confirmed  by  renal  
Location:  Olmsted  County, ’84­‘93  8.8 pathologist.  Case  identification: Record linkage  gives  details  of  virtually all  
US  ’94­‘03  17.5 medical  care provided.  
Fischer et al.  (36) 112 * * Not  Case  definition: WHO  classification.  Case  identification: Kidney  biospies  from 
Study  type:  Retrospective  given  patients  newly  diagnosed  with  IgA  at  the university  were  retrieved from inhouse  and  
Location:  New  Mexico  consultation  files.  
Kim  et al.  (34) 163 **  **  Not  Case  definition: Nephrotic  syndrome  defined  as  heavy  proteinuria,  edema and  
Study  type:  Retrospective  given  hypoalbuminemia;  some underwent  renal  biopsy.  Case identification: Record 
Location:  New  Orleans  review  and  two main  referral hospitals  
Sehic et al  (33) 17 **  * Not  Case  definition: Patients <  18 years and resident  in  study  area. Diagnosis  of  IgA  
Study  type:  Retrospective  given  nephropathy  made  by  renal biopsy.  
Location:  Shelby  County, 
Tennessee,  US  
Orta­Sibu  et al  (41) 505 **  ***  Not  Case  definition: <15 years; Acute  GN  with hematuria,  edema,  arterial 
Study  type:  Retrospective  given  hypertension  present. Nephrotic  syndrome  was diagnosed  on  the basis  of  
Location:  Venezuela  proteinuria greater than 40 mg/h  per  m2  body  surface area with or  without edema,  
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Study  Cases  RUE  ROE Biopsy 
rate  
Description  
hypoproteinemia  and  hypercholesterolemia.  Case  identification: Information  
obtained by  contacting  17 centres with a questionnaire.  Data  collected  by  chart 
review  of  patients.  
Mazzuchi  et al.  (15) 
Study  type:  Prospective 
Location:  Uruguay  
2058 ***  * Not  
given  
Case  definition: Diagnosed  by  biopsy;  defined  by  minimal  glomerular  lesions,  
levels  of  proteinuria,  serum creatinine,  arterial hypertension,  glomerular  filtration  
rate. Case  identification: National  registry 
RUE: risk of  underestimation; ROE: risk  of  overestimation; *  low;  ** medium;  *** high;  ESR: erythrocyte sedimentation  rate; ANA:  anti­nuclear  
antibodies;  GBM:  glomerular  basement  membrane;  ELISA  enzyme­linked  immunosorbent  assay; biopsy  rate: /100 000/year  
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Figure  2:  Incidence  of  glomerulonephritis in  children  and  adolescents.  
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Figure  3:  Incidence  in adults  or  those  of  all  ages  
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Appendix 
Figure 1a: Data abstraction forms 
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Table 1A: Incidence  rates by  type  of  glomerulonephritis;  rates  are crude  and  presented  in  units  of  /100  000  /year unless  
otherwise  specified.  
Ref  Race  Location  Time 
period  
Age  
range  
IgA 
nephropa 
thy 
Membranous 
nephropathy 
Membranopr  
oliferative  
GN  
Mesangial  
proliferativ  
e  GN  
Minimal  
change 
disease  
Focal  
segmental  
glomerulos  
clerosis  
Anti­
GBM  
disease  
Postinfecti  
ous GN 
(43) All Sfax,  
Tunisia  
1977­90 >14 
years 
0.3 (0.2,  
0.6) § 
1.1 (0.8,  1.4)§  3.1 (2.7,  3.6) 
§ 
1.2 (0.9,  
1.5)§ 
1.0 (0.8,  
1.3)§ 
(42) Asian Yonago  
City, 
Japan  
1983­
1999 
<15 
years 
4.5 
(11) Caucasian  Victoria, 
Australia 
1995, 
97 
All M: 5.7, F:  
2.9 
M: 1.8, F:  0.8 M: 0.3, F:  0.2 M: 0.7, F:  
0.4 
M: 2.5, F:  
1.8 
M: 0.2, 
F:  0 
(3)  non­
Polynesian 
Polynesian 
New 
Zealand  
1972­83 >  14 
years 
0.55‡ 
0.22‡ 
0.43‡ 
0.58‡ 
0.15‡ 
0.74‡ 
0.23‡ 
0.7‡ 
0.26‡ 
0.35‡ 
0.42 ‡ 
0.3 ‡  
0.16‡ 
0.25‡ 
0.26‡ 
0.53‡ 
(16) All French 
Polynesia 
2007 <15 
years 
18 
(17) Caucasian  East  
France 
1988 > 15 
years 
4.02 
(3.59, 
4.46)¶ 
(19) Caucasian  Rhone­
Alps,  
France 
1987­88 All 2.7 (2.5,  
3.0) ¶ 
1.2 (1.0,  1.4) 
¶ 
0.6 (0.5,  0.7) 
¶ 
0.7 (0.6,  
0.9)¶ 
(18) Caucasian  Picardy,  
France 
1976­80 
1981­85 
>  15 
years 
0.95 
(0.60, 
1.24) ¶ 
1.51 
(1.10,1.93 
0.52 
(0.26,0.74)¶ 
1.03 
(0.69,1.38) ¶ 
0.83 (0.50, 
1.10) ¶ 
0.26 
(0.09,0.44) ¶  
0.18 
0.65 
0.24 
(0.07,0.40) 
¶ 
0.23 
(0.00,0.19) 
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Ref  Race  Location  Time 
period  
Age  
range  
IgA 
nephropa 
Membranous 
nephropathy 
Membranopr  
oliferative  
Mesangial  
proliferativ  
Minimal  
change 
Focal  
segmental  
Anti­
GBM  
Postinfecti  
ous GN 
thy GN  e  GN  disease  glomerulos  
clerosis  
disease  
) ¶ ¶  
(6)  Caucasian  Saint 
Brieuc, 
France 
1976­85 20­79 2.8 
1986­95 20­79 2.8 
1996­ ≥ 20 2.6 
2002 
(6)  Caucasian  St. Brieuc, 
France 
1976­90 0­79 M: 0.9, F:  0.3 
(6)  Caucasian  St. Brieuc, 
France  
1976­90 10­79 M: 4.8, F:  
1.4, B: 
1.4 (1.1,1.7)¶ 0.45 
(0.29,0.62)¶ 
0.8 
(0.6,1.1)¶ 
2.7 
(2.2,3.0)¶ 
(6)  Caucasian  Saint 
Brieuc, 
France 
1976­85 20­59 
60­79 
1.0 
2.8 
1986­95 20­59 1.1 
60­79 3.3 
1996­
2002 
20­59 
60­79 
0.6 
1.7 
≥ 80 0.9 
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Ref  Race  Location  Time 
period  
Age  
range  
IgA 
nephropa 
Membranous 
nephropathy 
Membranopr  
oliferative  
Mesangial  
proliferativ  
Minimal  
change 
Focal  
segmental  
Anti­
GBM  
Postinfecti  
ous GN 
thy GN  e  GN  disease  glomerulos  
clerosis  
disease  
(4)  Caucasian  St. Brieuc, 
France 
1976­90 >  60 
years 
1.0 
(0.5,1.6)¶ 
2.5 (1.7,3.3)¶ 0.4 (0.1,0.8)¶  0.7 
(0.3,1.2)¶ 
(45) Caucasian  St. Brieuc, 
France 
1976­90 10­79 0.55 0.55 
(2)  Caucasian  Saint 
Brieuc, 
France 
1976­85 20­59 
60­79 
0.9 
0.5 
1986­95 20­59 0.1 
60­79 0.2 
1996­
2002 
20­59 0.2 
(5)  Caucasian  Italy 1993 All 0.84 0.49 0.14 0.19 0.16 0.23 0.01 0.07 
(25) Caucasian  Italy 1992­94 0­15 0.31 0.015 0.075 0.16 0.23 0.14 0.035 
(9)  Caucasian  City or 
Province 
1990­94 ≥  15 M: 2.27, 
F:  0.67, 
M: 1.84, F:  
0.79, B: 1.31 
M: 0.24, F:  
0.14, B: 0.19 
M: 0.36, 
F:  0.27, 
M: 0.62, F:  
0.49, B: 
of Turin, B: 1.47 B: 0.32 0.55 
Italy 
(28) Caucasian  Western 
Finland 
1980­
2000 
All UH  5.0  UH  1.4  
CH 0.8 
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Ref  Race  Location  Time 
period  
Age  
range  
IgA 
nephropa 
Membranous 
nephropathy 
Membranopr  
oliferative  
Mesangial  
proliferativ  
Minimal  
change 
Focal  
segmental  
Anti­
GBM  
Postinfecti  
ous GN 
thy GN  e  GN  disease  glomerulos  
clerosis  
disease  
(44) Caucasian  Denmark 1985­97 All 0.48 0.21 1.08 0.73 0.57 
(0.4,0.51) ¶ (0.16,0.24)¶ (0.94,1.01)¶ (0.62,0.75 (0.48,0.59)¶ 
)¶ 
(21) Caucasian  Heerlen,  
Maastricht  
and 
1978­84 16­65 
years 
1.9 0.9 0.6 0.9 
Sittard, 
The  
Netherlan 
ds  
(14) Caucasian  Spain  1994­99 All ages  0.79 0.62 0.36 0.48 0.64 
(20) Caucasian  Spain  1977­86 > 14 0.35 0.18 (0.17, 
years (0.33,0.37 0.20)§ 
) § 
(29) All Northern 1976­05 >16 0.99 0.75 (0.66, Type  1: 0.24 0.25 0.20, 0.15 (0.11, 
Ireland,  
UK 
years (0.88, 
1.09) ¶ 
0.84) ¶ (0.19, 0.29) ¶ 
Type  2: 0.03 
0.30) ¶ 0.18) ¶ 
(0.01, 0.04) ¶ 
(23) Leicesters  1973­82 0­15 
Prima hire, UK  
ry Asian (i.e.  City 12.1 
nephr 11.9% of Rest of 6.2 
otic population  country 
syndr )  
ome Non­Asian City 0.4 
Rest of 1.6 
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Ref  Race  Location  Time 
period  
Age  
range  
IgA 
nephropa 
Membranous 
nephropathy 
Membranopr  
oliferative  
Mesangial  
proliferativ  
Minimal  
change 
Focal  
segmental  
Anti­
GBM  
Postinfecti  
ous GN 
thy GN  e  GN  disease  glomerulos  
clerosis  
disease  
country 
(24) All Yorkshire, 1987­98 0­15 2.3 (2.0­
Prima UK  2.6) 
ry 
nephr South 7.4 (5.3­
otic  Asian 9.5) 
syndr Not South 1.6 (1.3­
ome  Asian 1.8) 
(22) All Birmingha 
m, UK  
1979­83 0­16 5.3 (3.7,  
7.0) ¶ 
Afro­
Caribbean  
3.4 (0,  
8.1) ¶ 
Asian 15.6 (9.6,  
21.9) ¶ 
Asian 2.6 (1.3,  
4.0) ¶ 
(27) Caucasian  Czech 1994­ All 1.12 0.30 (0.26, 0.15 (0.13, 0.37 (0.32, 0.40 0.35 (0.31, 
Republic  2000 (1.04, 0.34) ¶ 0.18) ¶ 0.40) ¶  (0.35, 0.39) ¶ 
1.19)¶ 0.45) ¶ 
(26) Caucasian  Moldova 
and 
2004 >18 
years 
0.53 0.93 1 0.73 0.33 
Banat, 
Romania 
(30) All Serbia  1987­06 >18 
years 
0.85 1.24 0.61 1.08 0.19 1.11 
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Ref  Race  Location  Time 
period  
Age  
range  
IgA 
nephropa 
Membranous 
nephropathy 
Membranopr  
oliferative  
Mesangial  
proliferativ  
Minimal  
change 
Focal  
segmental  
Anti­
GBM  
Postinfecti  
ous GN 
thy GN  e  GN  disease  glomerulos  
clerosis  
disease  
(38) All Bahrain 1990­ All  0.01 0.35 (0.23, 0.38 (0.25, 0.79 0.62 (0.45, 0.08 (0.02, 
2002 (0.00, 0.48)§ 0.50)§ (0.60, 0.79) § 0.14)§ 
0.03) § 0.97)§ 
(39) Arabian  Bahrain 2003­06 All 0.26 0.22 (0.04, 0.37 (0.14, 0.15 0.30 (0.09, 0.11 (0.00, 
and non­ (0.07,0.46 0.40)§ 0.60)§ (0.00, 0.51)§ 0.24) § 
Arabian  ) §  0.30)§ 
(13) Kuwaiti  Kuwait  1995­ All M: 2.5, F:  M: 0.8, F:1.4,  9.2 M: 1.8, F:  
national 2001 1.0, B: B: 1.1  1.1, B: 1.4  
1.7 
(40) Kuwaiti  
national 
Kuwait  1981­85 0­15 7.2 (5.3,  
9.1)¶ 
(37) Arabian¹  Benghazi, 
Libya  
1980­82 0­15 11.6 (6.4,  
16.9) ¶ 
(31) Caucasian  Ottawa­
Hull  
1985­93 6 
months 
0.05 (0,  0.14) 
¶ 
0.05 (0,  0.14) 
¶ 
2.81 
(2.10, 
0.37 (0.11, 
0.63) ¶ 
region, ­ 19 3.52) ¶ 
Canada  years 
1993­
2002 
0.09 (0,  0.21) 
¶ 
0 2.47 
(1.81, 
0.94 (0.54, 
1.34) ¶ 
3.12) ¶ 
(32) Caucasian  Central 
and 
1975­84 All M: 0.92, 
F:  0.34, 
Eastern  B: 0.62 
Kentucky, 
US  
(0.47,0.76 
)¶  
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Ref  Race  Location  Time 
period  
Age  
range  
IgA 
nephropa 
Membranous 
nephropathy 
Membranopr  
oliferative  
Mesangial  
proliferativ  
Minimal  
change 
Focal  
segmental  
Anti­
GBM  
Postinfecti  
ous GN 
thy GN  e  GN  disease  glomerulos  
clerosis  
disease  
1985­94 M: 1.43, 
F:  0.65, 
B: 1.02 
(0.84,1.21 
)¶  
(35) Caucasian  Olmsted  1974­03 All 1.4 (1.0,  0.7 (0.4,  1.0) 0.4 (0.2,  0.7) 0.3 (0.1,  1.1 (0.7,  
County, 1.8) 0.5) 1.5) 
US  
(36) All New 2000­05 All 0.93 
Mexico (0.75. 
1.11) ¶ 
(34) Caucasian  New 1994­03 1­18 1.81 
Disea  and Orleans,  years (1.53, 
se  African US  2.09) ¶  
define  American 
d as  
nephr  
otic 
syndr 
ome 
(33) African­ Shelby  1975­84 <  18 0.08 
American County, 
Tennessee  
years (0.01, 
0.46) 
,  US  
Caucasian  0.56 (0.2  
1.22) 
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Ref  Race  Location  Time 
period  
Age  
range  
IgA 
nephropa 
Membranous 
nephropathy 
Membranopr  
oliferative  
Mesangial  
proliferativ  
Minimal  
change 
Focal  
segmental  
Anti­
GBM  
Postinfecti  
ous GN 
thy GN  e  GN  disease  glomerulos  
clerosis  
disease  
African­ 1985­94 0.57 
American (0.23, 
1.18) 
Caucasian  0.3 (0.06, 
0.87) 
(41) All Venezuela 1998 <15 
years 
0.03 (0,  
0.1) §¶  
2.4 (2.0,  
2.7) §¶  
(15) All Uruguay 1990­94 All 0.24 0.16 0.06 0.4 0.67 
1995­99 0.46 0.31 0.10 0.55 0.99 
0.45 0.40 0.14 0.46 0.64 
Notes:  ‡  incidence  rate adjusted for age;  §  incidence  rate calculated  from data  given  in  the paper;  ¶ CI  calculated  from data  given in  paper  using  
standard  Normal  distribution;  ¹  Terminology  as  given  in  paper;  UH  University  hospital;  CH central hospital  
40 
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